Anthera Receives Positive Nasdaq Listing Determination

Biotech Investing

Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that on January 24, 2018, Anthera received formal notice that the Nasdaq Hearings Panel granted Anthera’s request for inclusion on The Nasdaq Capital Market. As quoted in the press release: Anthera’s continued listing on The Nasdaq Capital Market is subject to compliance with all applicable requirements by May 14, 2018. Anthera’s …

Anthera’s continued listing on The Nasdaq Capital Market is subject to compliance with all applicable requirements by May 14, 2018.
Anthera’s common stock will list on the Nasdaq Capital Market commencing with the open of business on Friday, January 26, 2018 and will continue to trade under the symbol “ANTH” on Nasdaq. Anthera does not expect the transfer to have an impact on trading and shares.

Click here to read the full press release.

anthera pharmaceuticals Biotech Investing